Nancy Stuart - 28 Jan 2022 Form 4 Insider Report for CONCERT PHARMACEUTICALS, INC.

Role
Chief Operating Officer
Signature
/s/ Jeffrey A. Munsie, attorney-in-fact
Issuer symbol
N/A
Transactions as of
28 Jan 2022
Net transactions value
$0
Form type
4
Filing time
01 Feb 2022, 15:06:07 UTC
Previous filing
07 Jan 2022
Next filing
16 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNCE Common Stock Award +99,000 +58% 269,386 28 Jan 2022 Direct F1, F2
transaction CNCE Common Stock Award +21,400 +7.9% 290,786 28 Jan 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in equal annual installments over a three-year period measured from the date of grant. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.
F2 Not applicable.
F3 Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest one business day after the date on which the Food and Drug Administration notifies the Issuer that it has accepted for filing a New Drug Application for CTP-543, provided that the date of acceptance is on or before a certain date in 2023. The amount listed represents the maximum number of shares that may be delivered pursuant to the grant.